GSK has entered a research collaboration with China-based LTZ Therapeutics to develop up to four first-in-class myeloid cell engagers (MCEs) for blood cancers and solid tumours through an exclusive option agreement providing an USD 50 million upfront payment, with eligibility for development, regulatory and commercial milestones plus tiered royalties. The MCE platform engages tissue-resident immune cells representing the majority of tumour-infiltrating populations, enabling broad and sustained anti-tumour activity with potential safety advantages over existing immunotherapies requiring hospital administration.

MCDs represent an emerging immuno-oncology class bridging innate immunity with targeted cancer cell killing through selective activation of myeloid populations in the tumour microenvironment (TME). LTZ previously partnered with Eli Lilly in 2025 for autoimmune disease applications using same technology platform.

According to PharmCube's NextBiopharm® database, this is GSK's 8th deal so far in 2025. Click here to request a free trial for NextBiopharm®.